Publication: Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study
| dc.contributor.author | YILMAZ, YUSUF | |
| dc.contributor.author | KEKLİKKIRAN, ÇAĞLAYAN | |
| dc.contributor.authors | YILMAZ Y., Toraman A. E. , Alp C., Dogan Z., Keklikkiran C., Stepanova M., Younossi Z. | |
| dc.date.accessioned | 2022-12-02T12:57:33Z | |
| dc.date.accessioned | 2026-01-11T15:57:00Z | |
| dc.date.available | 2022-12-02T12:57:33Z | |
| dc.date.issued | 2022-11-01 | |
| dc.description.abstract | Background Patients with non-alcoholic fatty liver disease (NAFLD) and more advanced fibrosis tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Aim To assess the association of PROs with select non-invasive tests (NITs) for fibrosis including FAST, Agile 3+ and Agile 4 scores Methods We enrolled patients with an established diagnosis of NAFLD who were seen in a tertiary care clinic into the NAFLD/NASH Registry. The FAST, Agile 3+ and Agile 4 scores were calculated using liver stiffness measurements by transient elastography and laboratory parameters. PROs were assessed using FACIT-F, CLDQ-NASH and WPAI instruments (total of 17 domain and summary scores). Results There were 1509 patients with NAFLD (mean age: 49 +/- 11 years, 50% men, 41% employed, 30% advanced fibrosis and 20% cirrhosis). The mean FAST, Agile 3+ and Agile 4 scores were 0.39 +/- 0.26, 0.35 +/- 0.31 and 0.12 +/- 0.23, respectively. Subjects with lower FAST, Agile 3+ and Agile 4 scores had the highest scores in select domains of FACIT-F, CLDQ-NASH and WPAI (p < 0.05 in comparison to subjects with elevated or high-risk NIT scores). Correlations with continuous NITs were significantly negative for Emotional and Functional well-being (FACIT-F), Activity/energy, Systemic symptoms, Worry and total scores (CLDQ-NASH), and Activity of WPAI (p < 0.05); the strongest was for Worry (CLDQ-NASH) with FAST (R = -0.17, p < 0.0001). The PRO scores of patients with NAFLD were lower than those of matched patients with chronic hepatitis B (p < 0.05 for 9/17 domain and summary scores). Conclusion Patients with NAFLD and high FAST, Agile 3+ or Agile 4 scores experience impairment of health-related quality of life. | |
| dc.identifier.citation | YILMAZ Y., Toraman A. E. , Alp C., Dogan Z., Keklikkiran C., Stepanova M., Younossi Z., "Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022 | |
| dc.identifier.doi | 10.1111/apt.17301 | |
| dc.identifier.endpage | 9 | |
| dc.identifier.issn | 0269-2813 | |
| dc.identifier.startpage | 1 | |
| dc.identifier.uri | https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.17301 | |
| dc.identifier.uri | https://hdl.handle.net/11424/283484 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Tıp | |
| dc.subject | Temel Eczacılık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Gastroenteroloji-(Hepatoloji) | |
| dc.subject | Eczacılık | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Temel Bilimler | |
| dc.subject | Medicine | |
| dc.subject | Basic Pharmaceutics Sciences | |
| dc.subject | Internal Medicine Sciences | |
| dc.subject | Internal Diseases | |
| dc.subject | Gastroenterology and Hepatology | |
| dc.subject | Pharmacology and Therapeutics | |
| dc.subject | Life Sciences | |
| dc.subject | Health Sciences | |
| dc.subject | Natural Sciences | |
| dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | FARMAKOLOJİ VE ECZACILIK | |
| dc.subject | Farmakoloji ve Toksikoloji | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | GASTROENTEROLOGY & HEPATOLOGY | |
| dc.subject | CLINICAL MEDICINE | |
| dc.subject | Clinical Medicine (MED) | |
| dc.subject | PHARMACOLOGY & PHARMACY | |
| dc.subject | PHARMACOLOGY & TOXICOLOGY | |
| dc.subject | Life Sciences (LIFE) | |
| dc.subject | Farmakoloji | |
| dc.subject | Farmakoloji, Toksikoloji ve Eczacılık (çeşitli) | |
| dc.subject | Genel Farmakoloji, Toksikoloji ve Eczacılık | |
| dc.subject | Farmakoloji (tıbbi) | |
| dc.subject | Hepatoloji | |
| dc.subject | Gastroenteroloji | |
| dc.subject | İlaç Rehberleri | |
| dc.subject | Pharmacy | |
| dc.subject | Pharmacology | |
| dc.subject | Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | |
| dc.subject | General Pharmacology, Toxicology and Pharmaceutics | |
| dc.subject | Pharmacology (medical) | |
| dc.subject | Hepatology | |
| dc.subject | Gastroenterology | |
| dc.subject | Drug Guides | |
| dc.title | Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study | |
| dc.type | article | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
